856 results on '"Uchi, Hiroshi"'
Search Results
2. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes.
3. Long‐term follow‐up results from KEYNOTE‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma
4. Antioxidant cinnamaldehyde attenuates UVB-induced photoaging
5. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system
6. Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases
7. Optimal strategy in managing advanced melanoma
8. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
9. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes
10. Protective role of 6-formylindolo[3,2-b]carbazole (FICZ), an endogenous ligand for arylhydrocarbon receptor, in chronic mite-induced dermatitis
11. The role of the OVOL1–OVOL2 axis in normal and diseased human skin
12. Evaluation of mapping biopsies for extramammary Paget disease: A retrospective study
13. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
14. Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
15. 6-Formylindolo[3,2-b]Carbazole Accelerates Skin Wound Healing via Activation of ERK, but Not Aryl Hydrocarbon Receptor
16. Potential role of the OVOL1–OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma
17. Dioxin-induced increase in leukotriene B4 biosynthesis through the aryl hydrocarbon receptor and its relevance to hepatotoxicity owing to neutrophil infiltration
18. Optimal strategy in managing advanced melanoma.
19. Adverse events associated with postoperative outcomes of adjuvant anti‐PD‐1 antibody therapy in both acral and non‐acral cutaneous melanomas: A multicenter, observational, post hoc analysis study.
20. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
21. Inhibition of aryl hydrocarbon receptor signaling and induction of NRF2-mediated antioxidant activity by cinnamaldehyde in human keratinocytes
22. Current state of yusho and prospects for therapeutic strategies
23. Adverse events associated with postoperative outcomes of adjuvant anti‐PD‐1 antibody therapy in both acral and non‐acral cutaneous melanomas: A multicenter, observational, post hoc analysis study
24. Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results
25. A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors
26. Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma
27. Effects of dioxin-related compounds on bone mineral density in patients affected by the Yusho incident
28. Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases
29. Figure S6 from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
30. Supplementary Data from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
31. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor
32. Current skin symptoms of Yusho patients exposed to high levels of 2,3,4,7,8-pentachlorinated dibenzofuran and polychlorinated biphenyls in 1968
33. Yusho and its latest findings—A review in studies conducted by the Yusho Group
34. The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients
35. Long-Term Health Effects of PCBs and Related Compounds: A Comparative Analysis of Patients Suffering from Yusho and the General Population
36. Pathogenesis of systemic sclerosis—current concept and emerging treatments
37. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
38. Acral lentiginous melanoma: Who benefits from sentinel lymph node biopsy?
39. 2,3,4,7,8-Pentachlorodibenzofuran is far less potent than 2,3,7,8-tetrachlorodibenzo-p-dioxin in disrupting the pituitary–gonad axis of the rat fetus
40. Filaggrin loss-of-function mutations are not a predisposing factor for atopic dermatitis in an Ishigaki Island under subtropical climate
41. Resveratrol inhibition of human keratinocyte proliferation via SIRT1/ARNT/ERK dependent downregulation of aquaporin 3
42. Neuronatin is related to keratinocyte differentiation by up-regulating involucrin
43. Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases.
44. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma
45. Melanoma and Immune Checkpoint Inhibitors
46. A case report of primary malignant melanoma of male urethra with distinct appearance in multiple regions
47. Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan
48. Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan
49. Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study
50. Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.